Available Until 12/31/2022

Innovations in Oncology: Focus on Lung Cancer

Course Description:


The emergence of novel targeted therapies and regimens for non-small cell lung cancer (NSCLC), including both those developed initially for NSCLC and those that were first approved for other solid organ tumors, has led to important changes in the treatment of both early-stage and metastatic disease in recent years. Additional promising therapies and novel treatment approaches are currently under investigation, such as treatments that target resistance to targeted therapies, and those that implement molecular and genetic testing to guide treatment selection. During this session, presenters will discuss recent evidence-based treatment innovations, recent changes to treatment guidelines, and explore emerging innovations that may impact NSCLC management in the future. Novel therapies in development including potential roles in treatment, and thresholds of evidence required for selecting treatments for individual patients will be discussed.

Learning Objectives:


At the completion of this knowledge-based activity, participants will be able to:

  1. Describe the incidence and current treatment landscape of non-small cell lung cancer (NSCLC).
  2. Discuss recently approved novel treatment approaches for NSCLC and their pharmacology. 
  3. Recognize the mechanisms of action and potential impact of emerging treatment options on NSCLC treatment guidelines and recommendations.


Amber Cipriani, PharmD, BCOP

Precision Medicine Pharmacy Coordinator

UNC Health Medical Center

Durham, NC


Laura R. Bobolts, PharmD, BCOP

SVP, Clinical Strategy and Growth


Coconut Creek, FL

Schedule of Educational Activity:

This activity consists of an audio recording, pre-test assessment questions (not required to pass or continue), post-test questions (required to pass with a score of 70% or higher), and a specific activity evaluation.


The Academy of Managed Care Pharmacy (AMCP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

ACPE UAN: 0233-9999-21-035-H01-P • Activity Type: Knowledge-Based
Contact Hours: 0.5
Release Date: September 2, 2021 •  Expiration Date: December 31, 2022
Activity Fee: Free for Members and Non-Members

Participants should claim continuing pharmacy education (CPE) credit for this home study activity only if they have not claimed credit for the live activity presented at AMCP 2021 Virtual.CPE credit will be processed through the AMCP Learn portal and reported directly to CPE Monitor. Please allow 72 hours for processing and posting in your NABP account.

To receive credit for an online activity you must:

  • Review the full content of the activity.
  • Successfully complete the post-test (required to pass with a score of 70% or higher, it may be taken a maximum of three times).
  • Complete a specific activity evaluation.

Commercial Support:

This educational activity is supported by unrestricted educational grants from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and Novartis Pharmaceuticals Corporation.

As an accredited provider, AMCP strictly adheres to the ACPE Standards for Commercial Support and other relevant guidelines and standards to ensure the independence of continuing pharmacy education (CPE) activities. It is AMCP’s intent that all CPE activities be independent, objective, balanced, evidence-based, and free of any commercial bias.

System Technical Requirements/Viewing Requirements:

System Requirements Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating websites. View the minimum technical and system requirements for continuing education online learning activities.


Credit Information

Activity Number Credit Amount Accreditation Period
ACPE UAN #0233-9999-21-035-H01-P 0.5 Contact Hours September 02, 2021 - December 31, 2022